Amsterdam Medical Center creates ‘hijacked’ medicine
September 13, 2021
Using a set of legal tricks, the pharmaceutical industry was able to turn an animal gallic acid into a medicine that costs tons of money
Daan Marselis
Daan Marselis (1983) has been working as a freelance journalist since the autumn of 2010. His work was published by the Dutch Journal of Medicine (‘Nederlands Tijdschrift voor Geneeskunde’), Trouw, de Volkskrant, de Correspondent, CNN, Vrij Nederland and several professional journals for health care executives. Marselis is currently working as a producer for Dutch radio station BNR Nieuwsradio. In December 2018, he joined The Investigative Desk, where he specialises in researching and writing about the pharmaceutical and health care industries.
Publications:
Only one in twenty-five Europeans infected report this through a COVID-19 app
May 22, 2021
The Dutch CoronaMelder app and its equivalents in other countries are used in around one in twenty-five COVID-19 cases. This has been shown by research
Data Covid-19 contact tracing apps
May 21, 2021
This data below is part of a cross-border investigation into corona-tech, called ‘Spooky Mayfly’. Journalists Dorien Vanmeldert, Tim Verheyden, and Bart Aerts (Belgium), Manon Dillen
The outrageous pricing model used by Big Pharma
April 17, 2021
Pharmaceutical firm Novartis charges €2 million for a single intravenous infusion — but the National Health Care Institute in the Netherlands declared in April that
‘As long as it is for free’
August 19, 2020
Most of the demand for (refresher) training courses for doctors in the Netherlands is fulfilled by industry- sponsored programmes. Even after decades of controversy over
From blockbuster to nichebuster
July 29, 2020
Two decades of EU market protection of ‘orphan’ (rare disease) medicines have greatly benefitted the industry. According to research by The Investigative Desk, published in
EMA rewrites medicine approval policy
May 26, 2020
New innovative medicines should be made available to European citizens more quickly. That is why the European Medicines Agency updates the process for market authorisation.
